8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Apr 20, 2026·SEC
Prelude Therapeutics Incorporated(PRLD)Earnings, Financials & Key Ratios
PRLD•NASDAQ
$4.97
Price updated Jul 7, 2026
AboutPrelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.Show more
- Revenue$12M+73.4%
- EBITDA-$103M+25.4%
- Net Income-$99M+21.8%
- EPS (Diluted)-1.29+23.2%
- Gross Margin85.91%-14.1%
- EBITDA Margin-847.24%+57.0%
- Operating Margin-861.33%+56.8%
- Net Margin-819.59%+54.9%
- ROE-99.45%-44.1%
PRLD Price & Volume
Prelude Therapeutics Incorporated (PRLD) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Outpaces Milestone Revenue Growth
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical cash runway deficiency
Key Thesis Takeaways
- Prelude Therapeutics faces a precarious financial outlook as its reliance on erratic milestone-driven revenue fails to offset high-intensity R&D expenditures.
- The company's rapid depletion of assets, which fell from $277.7 million in 2023Q4 to $119.6 million in 2026Q1, suggests an urgent need for additional capital to sustain its clinical pipeline.
- Investors should remain cautious regarding the firm's long-term viability given the accumulation of -$693.4 million in retained losses and the lack of a self-sustaining commercial revenue model.
Verdict Logic
the company's critical cash runway deficiency, evidenced by a cash balance of only $21.8 million against substantial ongoing clinical development costs, suggests a high probability of further dilutive equity financing.
PRLD Growth Metrics
Prelude Therapeutics Incorporated (PRLD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM138.86%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.14%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM37.28%
Return on Capital
10 Years-81.43%
5 Years-62.3%
3 Years-71.62%
Last Year-87.8%
PRLD Recent Earnings
Prelude Therapeutics Incorporated (PRLD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 0/12 qtrs (0%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.13+51.9%
$0.27
Rev
$5M+0.0%
$5M
Q2 2026
Mar 10, 2026Metric
Actual
Est
EPS
$0.20+39.4%
$0.33
Rev
$6M-72.7%
$21M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.26+25.7%
$0.35
Rev
$7M-68.3%
$21M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.41+8.9%
$0.45
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.13vs $0.27+51.9% | $5Mvs $5M+0.0% |
| Q2 2026 | Mar 10, 2026 | $0.20vs $0.33+39.4% | $6Mvs $21M-72.7% |
| Q4 2025 | Nov 12, 2025 | $0.26vs $0.35+25.7% | $7Mvs $21M-68.3% |
| Q3 2025 | Aug 14, 2025 | $0.41vs $0.45+8.9% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Prelude Therapeutics Incorporated (PRLD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.97 | $390.13M | -3.85 | 73.43% | -819.59% | -99.45% | — | |
| $190.46 | $40.49B | -32.01 | — | — | -83.22% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $8.59 | $554.24M | -6.71 | -0.3% | -247.54% | -44.39% | — | |
| $42.13 | $4.88B | -13.21 | — | — | -71.31% | — | |
| $16.22 | $2.09B | 7.84 | 20.38% | 99.97% | 64.48% | — |
Compare PRLD vs Peers
Prelude Therapeutics Incorporated (PRLD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRLD SEC Filings & Documents
Prelude Therapeutics Incorporated (PRLD) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PRLD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PRLD Frequently Asked Questions
Prelude Therapeutics Incorporated (PRLD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Prelude Therapeutics Incorporated's revenue?
Prelude Therapeutics Incorporated (PRLD) reported $16.7M in revenue for fiscal year 2025.
How fast is Prelude Therapeutics Incorporated growing?
Prelude Therapeutics Incorporated (PRLD) grew revenue by 73.4% over the past year. This is strong growth.
Is PRLD profitable?
Prelude Therapeutics Incorporated (PRLD) reported a net loss of $77.8M for fiscal year 2025.
Dividend & Returns
What is PRLD's return on equity?
Prelude Therapeutics Incorporated (PRLD) has a return on equity (ROE) of -99.5%. Negative ROE indicates the company is unprofitable.
What is Prelude Therapeutics Incorporated's free cash flow?
Prelude Therapeutics Incorporated (PRLD) had negative free cash flow of $43.8M in fiscal year 2025, likely due to heavy capital investments.